A groundbreaking clinical trial featuring the Corsano CardioWatch 287-2 is set to explore its potential in remote patient monitoring for individuals with cardiovascular diseases. Announced on January 10, 2026, this study is sponsored by Nova Scotia Health Authority and Corsano Health B.V. Stakeholders in cardiovascular health management, including clinical and regulatory teams, should take note of this development.
To help you navigate this update, here is what you will find in this article:
What is the study?
The upcoming trial focuses on assessing a wearable device, the Corsano CardioWatch 287-2, for managing cardiovascular conditions remotely. This device will be utilized for patients diagnosed with atherosclerotic cardiovascular disease (ASCVD) and congestive heart failure (CHF). Through remote patient monitoring, the study seeks to evaluate the device’s performance in tracking health-related biomarkers, potentially transforming how these chronic conditions are managed.
Sponsored by the Nova Scotia Health Authority and Corsano Health B.V., the trial emphasizes integration between novel technology and evidence-based care. This marks an important step in addressing the growing burden of cardiovascular diseases globally.
What changed?
The trial is currently listed as not yet recruiting on the ClinicalTrials.gov platform. Once recruitment begins, eligible participants will use the Corsano CardioWatch 287-2 to collect real-time health data. These innovations could significantly impact how healthcare providers and patients address chronic cardiovascular conditions across various care settings.
As this is an early-stage trial, clinical teams may wish to monitor updates related to its regulatory progress, study endpoints, and overall patient outcomes. Any advancement here is likely to influence future device development and healthcare protocols.
Who is affected?
This trial holds particular relevance for healthcare and regulatory professionals focused on wearable technologies and cardiovascular disease management. The Corsano CardioWatch 287-2 is designed to provide continuous monitoring of key health metrics, which could streamline the treatment of ASCVD and CHF patients.
Patients, clinicians, and policy regulators may all see significant benefits if the device meets performance and safety expectations. Clinical teams interested in digital health innovations will also find this trial valuable for research and practice purposes.
FAQ
- What conditions does the trial target?
The trial focuses on ASCVD management and congestive heart failure using remote patient monitoring.
- Who is sponsoring the study?
The trial is sponsored by Nova Scotia Health Authority and Corsano Health B.V.
- What is the status of the trial?
As of January 2026, the trial is listed as not yet recruiting participants.
- Why is this trial important?
It evaluates the real-world application of wearable technologies in managing chronic cardiovascular conditions, potentially leading to improved patient outcomes.
Conclusion
The planned clinical trial for the Corsano CardioWatch 287-2 represents a significant step in integrating advanced wearables into cardiovascular care. By harnessing the potential for precise and real-time remote monitoring, this study could set important benchmarks for future medical innovations. Stakeholders should monitor recruitment and trial advancements to understand its impact on clinical practice and regulatory pathways.
Disclaimer
This article is intended for informational purposes only and does not constitute legal advice. Professionals should consult relevant regulatory or legal experts regarding medical device compliance or clinical trial practices.
Further information
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07322510?term=medical+device